Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical is attractive because its ADHD franchise is showing meaningful momentum, with Jornay PM sales of $51.9M, up 24% year over year, and total ADHD revenue of $78.4M, while Azstarys adds a second differentiated growth engine in the same prescriber base. The company also appears to have better-than-feared durability in pain, as Belbuca generated $57.7M with recent access gains adding about 9M covered lives, and management sees no near-term generic launch activity despite investor concerns around 1/23/27. Fundamentally, the mix of rising ADHD prescriptions, a 190-person sales force, and resilient cash generation from legacy pain assets supports revenue growth and gives Collegium flexibility for share repurchases and business development.

Collegium Pharmaceutical is facing a deteriorating core pain franchise, with 2Q26 Nucynta franchise revenue of $35.2M, down 24% YoY, and Xtampza ER revenue of $45.0M, down 14% YoY, underscoring weakening demand and pricing pressure in shrinking opioid markets. Management’s own guidance cut by $40M on Nucynta and the uncertainty around Belbuca generic entry in 2027 make near-term revenue visibility poor, while REMS compliance, third-party supply dependence, and the need to support authorized generics add operational risk and margin pressure. Although Jornay PM and Azstarys offer longer-term growth potential, the stock’s fundamentals remain constrained by likely erosion in higher-margin pain products, lower authorized-generic economics, and the risk that new ADHD assets will not fully offset cash flow declines from the legacy portfolio.